We intend to change the landscape of healthcare through our nanotechnology!
The first way we intend to do this is via our novel theranostic oncology solution known as deep photoimmunotherapy (DEPIT). It's a high efficacy alternative to radiotherapy & chemotherapy targeting deep cancerous growths, with none of the nasty associated side effects of the typical aforementioned treatments. In its simplest form, DEPIT's method of action is a magnetic activation, releasing a modular, targeted payload alongside reactive oxygen species to eliminate cancer cells with high specificity; on top of this, targeting and imaging compounds are also integrated into the treatment structure, allowing wide-spectrum diagnosis and visualization.
Feel free to reach out regarding strategic partnership or employment opportunities. We are proud members of JLAB's innovation portfolio! (Johnson & Johnson Innovation Northeast)
Company Details
- Employees
- 2
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Competitors
- Mavis Tire, General Inception.
Ascellux Inc. Questions
Ascellux Inc.'s LinkedIn profile is https://www.linkedin.com/company/ascellux-inc
Ascellux Inc. has
2 employees.
View email and phone details for 2
employees at Ascellux Inc..
Ascellux Inc.'s industry is
Biotechnology Research
Ascellux Inc.'s top competitors are
Mavis Tire,
General Inception.
Ascellux Inc.'s categories are Biotechnology Research
Ascellux Inc.'s founding year is 2019
